Yeast infection symptoms, treatment, and prevention: what the evidence says

I have lost count of the number of patients who have told me some version of this story: "I bought the over-the-counter cream, it seemed to help for a few days, and then it came back." Or: "I've been treating myself for yeast infections for years, and I finally came in because nothing is working." When I examine them, approximately half do not actually have a yeast infection. They have bacterial vaginosis, a contact dermatitis, or another condition entirely. Self-diagnosis and self-treatment has created a cycle where many women are treating the wrong condition, while others with genuine recurrent candidiasis are not receiving the intensive regimen that would actually break the cycle.

Vaginal yeast infections are common — that is not in question. What deserves more attention is how often they are misdiagnosed (by women themselves and sometimes by clinicians), how the evidence-based treatment protocols differ from what many women are doing, and what we know about why some women develop recurrent infections that seem to resist every intervention.

This article covers the epidemiology, diagnosis, treatment, and prevention of vulvovaginal candidiasis based on the current clinical evidence, including the 2016 IDSA guidelines and the 2018 Lancet global burden analysis.

How common are yeast infections

Vulvovaginal candidiasis (VVC) is the second most common vaginal infection after bacterial vaginosis. The CDC estimates that 75% of women will experience at least one episode during their lifetime, and 40% to 45% will experience two or more. Between 5% and 8% of women develop recurrent vulvovaginal candidiasis (RVVC), defined as 4 or more symptomatic episodes within 12 months.

A 2018 systematic review by Denning and colleagues, published in The Lancet Infectious Diseases, estimated the global burden at approximately 492 million episodes of VVC per year, with 138 million women affected by recurrent disease annually. The authors characterized RVVC as "a neglected chronic condition that causes substantial morbidity and has significant economic consequences."

A 2017 epidemiological analysis by Blostein and colleagues in Annals of Epidemiology found that the annual incidence of VVC in the United States was approximately 29 per 100 women of reproductive age. Incidence peaks between ages 20 and 40 and declines after menopause (as lower estrogen levels create a less favorable environment for Candida growth).

The economic burden is not trivial. OTC antifungal products represent a market of over $400 million annually in the United States alone. When you add healthcare visits, prescription medications, and lost productivity, the annual cost attributable to VVC is estimated at over $1.8 billion in the U.S.

Symptoms

The classic symptoms of vulvovaginal candidiasis are well-defined, though not all women experience the full constellation:

• Itching and irritation: Intense vulvar and vaginal itching is the most common symptom and is present in over 90% of confirmed cases. The itching is typically persistent, may worsen at night, and can range from mild to severe enough to interfere with daily activities.
• Burning sensation: Burning, particularly during urination (vulvar contact with urine) and during intercourse (entry dyspareunia). The burning is external (vulvar), not internal (which would suggest a UTI).
• Discharge: The textbook description is a thick, white, odor-free discharge with a cottage cheese-like consistency. However, discharge varies considerably — it can be thin and watery, or there may be minimal discharge at all. The key distinguishing feature is the absence of a foul or fishy odor (which would suggest bacterial vaginosis).
• Redness and swelling: Vulvar erythema (redness) and edema (swelling) are common, sometimes extending to the inner thighs. In severe cases, fissures (small cracks) in the vulvar skin can develop.
• Vaginal soreness: A general feeling of rawness or irritation, particularly after intercourse.

An important caveat: these symptoms are not exclusive to yeast infections. Bacterial vaginosis, trichomoniasis, contact dermatitis, lichen sclerosus, and desquamative inflammatory vaginitis can all produce similar symptoms. This overlap is why self-diagnosis is unreliable.

What causes yeast infections

Candida species are normal residents of the vaginal flora. In a healthy vaginal ecosystem, Candida coexists at low levels with Lactobacillus bacteria, which produce lactic acid and hydrogen peroxide to maintain an acidic pH (3.8 to 4.5) that keeps fungal growth in check. A yeast infection occurs when this balance is disrupted and Candida proliferates.

Candida albicans is responsible for 85% to 90% of vulvovaginal yeast infections. Non-albicans species (primarily C. glabrata, C. tropicalis, C. parapsilosis, and C. krusei) account for the remaining 10% to 15% and are clinically important because they are often resistant to standard antifungal treatments, particularly fluconazole.

The shift from commensal (harmless resident) to pathogenic (infection-causing) Candida is driven by changes in the vaginal environment. When conditions favor Candida growth — higher pH, reduced Lactobacillus populations, excess glucose, immunosuppression — the fungus transitions from its yeast form to a hyphal (filamentous) form that invades vaginal epithelial cells and triggers the inflammatory response that produces symptoms.

Risk factors

Several factors are consistently associated with increased risk of vulvovaginal candidiasis:

Antibiotic use. Antibiotics are the single most common precipitant of yeast infections. Broad-spectrum antibiotics kill Lactobacillus along with the targeted pathogen, removing the primary competitive inhibitor of Candida growth. The risk is highest with broad-spectrum penicillins, cephalosporins, and fluoroquinolones, and increases with longer courses of therapy.

Hormonal factors. Elevated estrogen levels increase glycogen in vaginal epithelial cells, which Candida metabolizes as a nutrient source. This explains why yeast infections are more common during pregnancy (when estrogen is markedly elevated), in the luteal phase of the menstrual cycle (after ovulation, when estrogen and progesterone are higher), and in women taking high-dose estrogen oral contraceptives. Conversely, yeast infections are less common after menopause, when estrogen is low.

Diabetes. Poorly controlled diabetes (both type 1 and type 2) increases vaginal glucose levels and impairs immune function, significantly raising the risk of VVC. Recurrent yeast infections can be an early indicator of undiagnosed diabetes or prediabetes.

Immunosuppression. Women taking immunosuppressive medications (corticosteroids, chemotherapy, biologic agents), women with HIV (particularly with CD4 counts below 200), and women with other immunocompromising conditions are at significantly higher risk.

Sexual behavior. Yeast infections are not sexually transmitted, but sexual activity can be a contributing factor. Receptive oral sex is associated with increased VVC risk (possibly because oral Candida is introduced vaginally). Frequent intercourse and the use of spermicides also increase risk.

Vaginal practices. Douching disrupts the vaginal flora and increases the risk of both yeast infections and bacterial vaginosis. Scented soaps, bubble baths, and vaginal deodorants can cause chemical irritation that mimics infection symptoms or alters the vaginal environment.

Getting an accurate diagnosis

The most important takeaway from the literature on yeast infection diagnosis is this: self-diagnosis is unreliable. A widely cited study found that only about 34% of women who believed they had a yeast infection actually had one when tested. The rest had bacterial vaginosis, mixed infections, or no infection at all (sometimes just contact irritation or a dermatological condition).

An accurate clinical diagnosis involves:

1. Symptom assessment: Nature of discharge, presence of itching/burning, odor, timing in relation to menstrual cycle.
2. Vaginal pH testing: Normal pH (≤4.5) supports candidiasis. Elevated pH (>4.5) suggests BV or trichomoniasis.
3. Wet mount microscopy: A sample of vaginal discharge examined under a microscope with saline and KOH (potassium hydroxide) preparation. KOH dissolves epithelial cells and bacteria, making yeast hyphae and budding yeast cells easier to see. Sensitivity is 40% to 60% for Candida detection.
4. Vaginal culture: The gold standard for diagnosis, particularly for recurrent or treatment-resistant infections. Culture identifies the specific Candida species, which guides treatment (non-albicans species often require different antifungals).

For a first episode that matches the classic presentation (intense itching, cottage cheese discharge, no odor), empiric treatment (treating without a lab-confirmed diagnosis) is reasonable. But for recurrent episodes, treatment failures, or atypical presentations, laboratory confirmation is essential. Treating the wrong condition repeatedly wastes time and money and delays resolution of the actual problem.

Treatment options

The 2016 IDSA guideline for candidiasis management remains the standard reference. Treatment is categorized by whether the infection is uncomplicated or complicated.

Uncomplicated VVC (80–90% of cases): Mild to moderate symptoms, sporadic occurrence, caused by C. albicans, in a non-immunocompromised patient.

• Oral: Fluconazole 150 mg, single dose. This is the most convenient option and has equivalent efficacy to topical regimens (80% to 95% cure rate at 1 to 2 weeks). It is preferred by most patients for its simplicity.
• Topical azoles: Clotrimazole, miconazole, or tioconazole in cream or suppository form. Available OTC in 1-day, 3-day, and 7-day regimens. All durations have similar overall cure rates for uncomplicated infections, though the 7-day regimen has slightly higher efficacy for more symptomatic cases.

Complicated VVC: Severe symptoms, recurrent infection (≥4/year), non-albicans species, or immunocompromised patient.

• Severe single episode: Fluconazole 150 mg given twice (day 1 and day 3), or a 7- to 14-day course of topical azole therapy.
• Non-albicans species (especially C. glabrata): These are often resistant to fluconazole. The IDSA guideline recommends intravaginal boric acid 600 mg in gelatin capsules once daily for 14 days as first-line therapy for C. glabrata infections. Alternative options include nystatin vaginal suppositories or topical amphotericin B.
• Pregnancy: Only topical azoles are recommended during pregnancy (fluconazole is contraindicated due to teratogenic risk at higher doses). A 7-day course of topical clotrimazole or miconazole is standard.

Recurrent yeast infections

Recurrent vulvovaginal candidiasis (RVVC) — defined as 4 or more symptomatic episodes within 12 months — affects approximately 5% to 8% of women of reproductive age. The 2018 Lancet analysis estimated 138 million women are affected globally. RVVC is not just an inconvenience — it significantly impairs quality of life, sexual function, mental health, and work productivity.

A 2016 review by Sobel in the American Journal of Obstetrics & Gynecology outlined the evidence-based management approach for RVVC:

Phase 1: Induction. Achieve clinical remission with an intensive short course. The standard regimen is fluconazole 150 mg on days 1, 4, and 7 (three doses over one week). This clears the acute infection and reduces the vaginal Candida burden to low levels.

Phase 2: Maintenance suppression. After induction, fluconazole 150 mg weekly for 6 months. This maintenance phase is critical and is what distinguishes RVVC management from the treatment of isolated episodes. Without it, recurrence rates exceed 50% within 3 months. With it, approximately 90% of women remain symptom-free during the maintenance period.

After maintenance: When the 6-month suppressive course ends, approximately 40% to 50% of women will experience recurrence within the following year. Some women require longer or repeated maintenance courses. The decision to extend therapy should be individualized based on recurrence patterns and the impact on quality of life.

For women with C. glabrata recurrence, boric acid maintenance (600 mg intravaginally 2 to 3 times weekly) can be used as a suppressive regimen after initial induction.

Recurrent yeast infection outcomes by treatment approach. Sources: Sobel (AJOG, 2016), IDSA Guideline (2016).

Prevention strategies

The evidence base for yeast infection prevention is less robust than for treatment, but several strategies have reasonable support:

Probiotics (Lactobacillus). Oral or vaginal Lactobacillus supplementation is one of the most commonly recommended prevention strategies, but the evidence is mixed. Several small RCTs have shown that specific strains (L. rhamnosus GR-1 and L. reuteri RC-14) reduce VVC recurrence when used alongside antifungal treatment. However, not all probiotic products contain effective strains at adequate colony counts. The IDSA guideline does not include probiotics in its standard recommendations due to inconsistent evidence, but the approach is low-risk and may benefit some women.

Avoid unnecessary antibiotics. Since antibiotics are the single most common precipitant, avoiding unnecessary use (especially broad-spectrum agents) is a meaningful prevention strategy. When antibiotics are medically necessary, some clinicians prescribe a single dose of fluconazole 150 mg at the end of the antibiotic course for women with a history of antibiotic-triggered yeast infections.

Blood sugar management. For women with diabetes, maintaining good glycemic control reduces VVC risk. This is also relevant for women with PCOS and insulin resistance. See our PCOS diet guide for nutritional strategies targeting insulin sensitivity.

Clothing and hygiene. Wearing cotton underwear, avoiding tight-fitting synthetic clothing in the genital area, and changing out of wet swimwear or exercise clothing promptly are commonly recommended. The evidence is largely observational, but the mechanisms are plausible (Candida thrives in warm, moist environments). Avoiding douching, scented soaps, and vaginal deodorants is more strongly supported — these products disrupt vaginal flora and pH.

Dietary changes. The popular belief that reducing sugar intake prevents yeast infections has biological plausibility (Candida metabolizes glucose) but limited direct evidence from clinical trials. For women with insulin resistance or poorly controlled diabetes, reducing glycemic load is clearly beneficial. For women with normal glucose metabolism, the effect of dietary sugar reduction on VVC is unproven but unlikely to be harmful.

When to see a doctor

Self-treatment with OTC antifungals is reasonable for a first or occasional episode with classic symptoms. However, see a healthcare provider in these situations:

• First-ever suspected yeast infection: Confirm the diagnosis before establishing a self-treatment pattern.
• Symptoms do not resolve with OTC treatment within 3 days.
• Symptoms recur within 2 months of treatment.
• 4 or more infections in 12 months (meets criteria for RVVC and requires a different management approach).
• Pregnancy: Oral fluconazole is contraindicated; clinical guidance on topical treatment is needed.
• Severe symptoms: Significant swelling, redness, fissures, or pain that prevents daily activities.
• Unusual symptoms: Foul-smelling discharge (suggests BV), green or frothy discharge (suggests trichomoniasis), or pelvic pain (suggests possible PID).
• Diabetes, HIV, or immunosuppression: Higher risk of complicated infection and non-albicans species.

If you experience vaginal symptoms alongside menstrual irregularities, our period calculator can help document the timing relationship between your cycle and infections. For concerns about STIs that can mimic yeast infection symptoms, see our STI statistics article.

Frequently asked questions about yeast infections

How do I know if it's a yeast infection or something else?

The only way to know for certain is with clinical testing. Self-diagnosis is correct only about 34% of the time. Classic yeast infection signs include intense itching, thick white odorless discharge, and normal vaginal pH. Bacterial vaginosis, by contrast, typically presents with a fishy odor and thin grayish discharge. Trichomoniasis produces yellow-green frothy discharge. If you are unsure, or if OTC treatment does not resolve symptoms within 3 days, see a provider for pH testing, microscopy, or culture.

Can men get yeast infections from women?

Yeast infections are not classified as sexually transmitted infections, but Candida can be transmitted to male sexual partners, particularly uncircumcised men. Male genital candidiasis (balanitis) presents as redness, itching, and white patches on the penis. It is uncommon in healthy men but more likely in those with diabetes or immunosuppression. Treating both partners is not routinely recommended unless the male partner is symptomatic.

Why do I keep getting yeast infections?

Recurrent VVC (4+ episodes/year) affects 5% to 8% of women. Common contributing factors include antibiotic use, uncontrolled diabetes, immunosuppression, hormonal changes (pregnancy, oral contraceptives), and host immune factors that are poorly understood. Non-albicans Candida species (especially C. glabrata) should be ruled out with culture, as they require different treatment. RVVC management requires a 6-month suppressive maintenance regimen, not just repeated treatment of individual episodes.

Do probiotics prevent yeast infections?

The evidence is mixed. Some small RCTs show that specific Lactobacillus strains (L. rhamnosus GR-1 and L. reuteri RC-14) reduce recurrence when used alongside standard treatment. However, many commercial probiotic products do not contain these specific strains at effective doses. The IDSA does not currently include probiotics in standard treatment guidelines. They are low-risk and may benefit some women, but they are not a substitute for antifungal treatment of active infections.

Is it safe to have sex with a yeast infection?

Sex during a yeast infection is not dangerous, but it is generally not advisable. Intercourse can worsen irritation and inflammation, delay healing, and cause discomfort or pain. Some topical antifungal products (creams and suppositories) can weaken latex condoms, increasing the risk of breakage. It is best to wait until symptoms have fully resolved before resuming sexual activity.

Can yeast infections go away on their own?

Mild yeast infections occasionally resolve without treatment, particularly if the precipitating factor (such as a course of antibiotics) has been removed. However, most symptomatic infections benefit from treatment, and leaving them untreated risks worsening symptoms and prolonged discomfort. Given the availability of effective OTC treatments, there is little reason to wait and see — unless you are uncertain of the diagnosis, in which case seeing a provider is the better option.